Lilly reaffirms commitment to Alzheimer's disease
This article was originally published in Scrip
Following news of its significant diabetes venture with Boehringer Ingelheim earlier this week (scripintelligence.com, 12 January 2010), Lilly's CEO Dr John Lechleiter was keen to highlight the firm's focus on Alzheimer's disease as also being key to its future growth, speaking at the JP Morgan healthcare in San Francisco conference this week.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.